(Reuters) - Allergan Inc is close to a buyout deal worth up to $65.5 billion (41.80 billion pounds) by Actavis Plc , one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.